Scientific Insights
Editorial articles exploring mass-spec technologies, clinical companion diagnostics, and trial patient stratification strategies.
Proteomics Strategy for Oncology Developers
These articles explain how discovery proteomics, pathway analysis, and companion diagnostic validation support early oncology trial decisions.
BY LYSATE ANALYSIS TEAM
JUNE 2026
Integrating Proteomics into Oncology Phase I/II Clinical Trials
Explore how B2B developers leverage global mass spectrometry to identify active kinases and bypass networks early in trial designs.
Read Article
BY CDX REGULATORY TEAM
JULY 2026
Transitioning Biomarkers to CLIA/CAP Assays
Key validation parameters (LOD, linear range, and precision profiles) required to transition mass-spec signatures to clinical CDx panels.
Scheduled Release